Vivos (RDGL) Stock Price, News & Analysis

Company Overview

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.

Key Stats

• Today's Range: $0.11 to $0.12
• 50-Day Range: $0.10 to $0.15
• 52-Week Range: $0.06 to $0.26
• Volume: 394,769 shs
• Average Volume: 895,928 shs
• Market Capitalization: $54.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Vivos Stock Analysis - MarketRank™

Vivos scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Vivos.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Vivos is -11.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vivos is -11.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Vivos has been sold short.

Short Interest Ratio / Days to Cover

Vivos has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vivos has recently decreased by 99.27%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vivos does not currently pay a dividend.

Dividend Growth

Vivos does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.00% of the float of Vivos has been sold short.

Short Interest Ratio / Days to Cover

Vivos has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vivos has recently decreased by 99.27%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Vivos this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vivos insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.50% of the stock of Vivos is held by insiders. A high percentage of insider ownership can be a sign of company health.

RDGL Stock Analysis - Frequently Asked Questions

How have RDGL shares performed this year?

Vivos' stock was trading at $0.1149 at the start of the year. Since then, RDGL stock has increased by 3.9% and is now trading at $0.1194.
View the best growth stocks for 2025 here.

How do I buy shares of Vivos?

Shares of RDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vivos own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vivos investors own include MannKind (MNKD), Agenus (AGEN), APA (APA), Aphria (APHA), Bionano Genomics (BNGO), Churchill Capital Corp IV (CCIV) and Canopy Growth (CGC).

Company Calendar

• Today: 6/12/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Finance
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:RDGL
• CIK: 1449349
• Web: www.radiogel.com
• Phone: (509) 736-4000
• Fax: 509-736-4007
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$2.89 million
• Net Margins: N/A
• Pretax Margin: -12,345.83%
• Return on Equity: N/A
• Return on Assets: -197.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 25.48
• Quick Ratio: 25.48

Sales & Book Value

• Annual Sales: $20 thousand
• Price / Sales: 2,707.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.02) per share
• Price / Book: -5.97

Miscellaneous

• Outstanding Shares: 453,512,000
• Free Float: 369,805,000
• Market Cap: $54.15 million
• Optionable: Not Optionable
• Beta: 1.06